Why the study?
Does abciximab therapy improve long-term clinical outcomes in diabetic patients compared to non-diabetic patients undergoing high-risk PCI?
Does abciximab therapy improve long-term clinical outcomes in diabetic patients compared to non-diabetic patients undergoing high-risk PCI?
In high-risk PCI, abciximab therapy in diabetic patients was effective for early clinical outcomes, but its long-term clinical benefits were not proven compared to non-diabetic patients.
No takes yet. Share an insight, caveat, or question.
Should not change abciximab use in high-risk PCI; leaves open differential long-term effects by diabetes status.
Sim et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: